Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Lung Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Esophageal Neoplasms 1

Interventions

Fluorouracil 11Cisplatin 10Radiotherapy 9Paclitaxel 7Trastuzumab 5Erlotinib Hydrochloride 5Specimen Handling 4Taxes 3Radiation 3Nivolumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Carboplatin 3trastuzumab biosimilar HLX02 2entinostat 2alvocidib 2Psychiatric Rehabilitation 2Plicamycin 2PF-05280014 2Oxaliplatin 2Ontruzant 2Ogivri 2Neoadjuvant Therapy 2Microarray Analysis 2Epirubicin 2Decitabine 2Celecoxib 2CT-P6 2Brachytherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Esophageal Neoplasms × Tetrahydrouridine × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡